Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-5500 in Participants With Prostate Cancer
NCT05997615Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Aug 2023
- Primary completion
- Sep 2027
- Modality
- Recombinant Proteins and Enzymes, T-cell Engagers
- Countries
- 4
01
Overview
Phase 1, open-label trial of SAR446329 in prostate cancer (PCa) (8 arms), sponsored by Astellas Pharma. Primary endpoints: Number of Participants With Adverse Events up to 80 months, Number of Participants With Treatment-Emergent Adverse Events up to 80 months and 4 more. Started Aug 2023; status: recruiting.
02
Drugs
SAR446329
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05997615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05997615.